Health Care & Hospital Law
Jan. 17, 2020
Judge considers dismissal in HIV drug case
Fighting a bid to dismiss the lawsuit, plaintiffs’ attorneys argued provisions in an agreement between four companies that prevent the creation of competing generics while any component of the drug formulation remains patented are anticompetitive.
SAN FRANCISCO -- The agreement between Gilead Sciences Inc. and partner companies that allegedly constitute a monopoly by restricting generic competition is the "market reality," an attorney for the HIV drugmaker argued before a federal judge Thursday.
Defense attorney Christopher Curan said federal antitrust law "acknowledges and encourages the competitive, efficiency-enhancing benefits of such collaborations," like the partnershi...
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In
